Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4515100 via SAD · 1 trial · 1 indication
SAEs of LY4515100
| Arm | Type | Description |
|---|---|---|
| LY4515100 of Part A (SAD) | EXPERIMENTAL | Single-ascending doses of LY4515100 will be given orally |
| LY4515100 of Part B (MAD) | EXPERIMENTAL | Multiple-ascending doses of LY4515100 will be given orally |
| LY4515100 and Itraconazole of Part C | EXPERIMENTAL | LY4515100 and Itraconazole will be given orally |
| LY4515100 and Metformin of Part C | EXPERIMENTAL | LY4515100 and Metformin will be given orally |
| LY4515100 and Transporter Substrates or Renal Marker of Part C | EXPERIMENTAL | LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV) |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo will be given orally |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo will be given orally |
| Name | Type | Description |
|---|---|---|
| LY4515100 via SAD | DRUG | given orally |
| LY4515100 via MAD | DRUG | given orally |
| LY4515100 | DRUG | given orally |
| Itraconazole | DRUG | given orally |
| Caffeine | DRUG | given orally |
| Digoxin | DRUG | given orally |
| Iohexol | DRUG | given IV |
| Metformin | DRUG | given orally |
| Rosuvastatin | DRUG | given orally |
| Placebo | DRUG | given orally |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring. * Have a body mass index within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive). * Individua...
LY4515100 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with an ongoing trial evaluating its effects in healthy volunteers. The drug is not yet approved and is still in the early stages of clinical research.
LY4515100 is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy participants.
LY4515100 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting healthy participants to evaluate the drug's safety and tolerability.
LY4515100 is being studied in a Phase 1 clinical trial with the identifier NCT07339722, titled "A Study of LY4515100 in Healthy Participants." This randomized, double-blind, placebo-controlled trial is recruiting 123 healthy adults in the United States.
LY4515100 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial, NCT07339722, is recruiting healthy participants to study the drug, but it has not yet received regulatory approval for any use.